眾生藥業(002317.SZ):眾生睿創擬通過增資擴股實施股權激勵
格隆匯5月22日丨眾生藥業(002317.SZ)公佈,公司控股子公司廣東眾生睿創生物科技有限公司(“眾生睿創”)為提高團隊的積極性、創造性,實現核心團隊與眾生睿創共同成長,將核心團隊利益與股東價值更加緊密結合起來,使其行為與眾生睿創的戰略目標保持一致,為眾生睿創長遠發展奠定良好的基礎,眾生睿創擬通過增資擴股方式實施股權激勵。
眾生睿創激勵對象合夥成立廣東博觀元創生物科技研究中心(有限合夥)(“元創生物”)對眾生睿創進行增資。公司放棄此次對眾生睿創增資的優先認購權。
公司同意控股子公司眾生睿創此次增資擴股,新增註冊資本人民幣1030.22萬元,由元創生物以人民幣2091.35萬元認繳本次新增注冊資本人民幣1030.22萬元,佔眾生睿創本次增資擴股後總股本的7.61%,超出部分計入眾生睿創的資本公積。
眾生睿創此次增資完成後,其註冊資本將增加至人民幣13530.22萬元,公司持股比例由74.00%變為68.37%,眾生睿創仍為公司控股子公司。同意授權公司董事長根據具體情況實施相關事宜並簽署有關協議及文件。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.